- Home
- NYT vs JAZZ Comparison
NYT vs JAZZ Comparison
Compare NYT & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYT
- JAZZ
- Stock Information
- Founded
- NYT 1851
- JAZZ 2003
- Country
- NYT United States
- JAZZ Ireland
- Employees
- NYT N/A
- JAZZ N/A
- Industry
- NYT Newspapers/Magazines
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- NYT Consumer Discretionary
- JAZZ Health Care
- Exchange
- NYT Nasdaq
- JAZZ Nasdaq
- Market Cap
- NYT 8.7B
- JAZZ 8.5B
- IPO Year
- NYT N/A
- JAZZ 2007
- Fundamental
- Price
- NYT $48.11
- JAZZ $136.91
- Analyst Decision
- NYT Buy
- JAZZ Strong Buy
- Analyst Count
- NYT 6
- JAZZ 15
- Target Price
- NYT $55.33
- JAZZ $190.87
- AVG Volume (30 Days)
- NYT 1.9M
- JAZZ 1.0M
- Earning Date
- NYT 05-07-2025
- JAZZ 04-30-2025
- Dividend Yield
- NYT 1.50%
- JAZZ N/A
- EPS Growth
- NYT 26.43
- JAZZ 41.75
- EPS
- NYT 1.77
- JAZZ 8.65
- Revenue
- NYT $2,558,919,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- NYT $8.41
- JAZZ $7.30
- Revenue Next Year
- NYT $5.95
- JAZZ $4.01
- P/E Ratio
- NYT $27.03
- JAZZ $15.53
- Revenue Growth
- NYT 6.66
- JAZZ 6.12
- 52 Week Low
- NYT $41.55
- JAZZ $99.06
- 52 Week High
- NYT $58.16
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- NYT 45.98
- JAZZ 55.43
- Support Level
- NYT $46.97
- JAZZ $133.99
- Resistance Level
- NYT $50.15
- JAZZ $141.36
- Average True Range (ATR)
- NYT 1.14
- JAZZ 4.82
- MACD
- NYT 0.25
- JAZZ -0.94
- Stochastic Oscillator
- NYT 58.44
- JAZZ 26.15
About NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the major source of revenue for both segments is subscription.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.